23:20:55 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaOB Match
Gentian Diagnostics är ett norskt bolag som utvecklar olika produkter inom hälsovård. Exempel är diagnostiska test med målet att utveckla och effektivisera diagnostisk behandling, vilket innefattar behandling utav cancer och hjärt- och kärlsjukdomar. En stor del av verksamheten innefattar FoU utveckling. Bolaget grundades 1998 och har sitt huvudkontor i Moss.


2022-10-27 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning GENT 0.00 NOK
2022-05-18 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning GENT 0.00 NOK
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 Ordinarie utdelning GENT 0.00 NOK
2018-02-27 Bokslutskommuniké 2017
2017-06-06 Årsstämma 2017
2021-12-16 08:47:19
Moss, 16 December 2021

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of innovative
and efficient diagnostics for better treatment decisions, has completed the
technical development of its novel SARS-Cov-2 antibody immunoassay. This will be
the first assay available on high-throughput open-access clinical chemistry
platforms for detection of antibodies against SARS CoV-2 virus. The assay will
be easily accessible and efficient, and holds potential to speed up the
determination of immunisation status in society and support vaccination efforts.

The company will now submit the required documentation for CE-marking of the
test and begin preparing for full-scale production. Finalisation of the
regulatory approval is expected to allow for a commercial launch of the
SARS-Cov-2 antibody assay in February 2022.

"The recent resurgence of Covid-19 cases highlights the need for reliable
high-throughput tests to manage the pandemic. With up to 2000 tests per hour we
are confident that our new SARS-Cov-2 test can increase capacity and laboratory
efficiency significantly. Our assay can be used on all instrument platforms with
no additional infrastructure or workflow costs.", says CEO Hilja Ibert in
Gentian Diagnostics.

The SARS-Cov-2 test will add to Gentian's diagnostics test portfolio including
four established products, the GCAL infection and inflammation assay, which is
in market development, and the NT-proBNP, congestive heart failure test which is
in product development.

For further information, please contact:
Hilja Ibert, CEO
+47 919 05 242 (mobile)

Njaal Kind, CFO and COO
+47 919 06 525 (mobile)

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures
high-quality, in vitro diagnostic reagents. Gentian's expertise and focus lies
within immunochemistry, specifically infections, inflammations, kidney failures
and congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is based in
Moss, Norway, serving the global human and veterinary diagnostics markets
through sales and representative offices in Sweden, USA and China. For more
information, please visit www.gentian.com.